MedPath

Therapeutic Drug Monitoring of Voriconazole

Not Applicable
Completed
Conditions
Mycoses
Interventions
Registration Number
NCT00890708
Lead Sponsor
Seoul National University Hospital
Brief Summary

The purpose of this study is to determine whether therapeutic drug monitoring of voriconazole is useful in the treatment of invasive fungal infection.

Detailed Description

Voriconazole is an anti-fungal agent, which is used in the treatment of invasive fungal infection, especially aspergillosis. The serious side effects of voriconazole include liver function abnormality, encephalopathy, etc. Recently, the several studies showed that the blood level of voriconazole is variable and it is associated with drug side effect and treatment outcome. However, there is no randomized controlled study which proves that therapeutic drug monitoring of voriconazole can improve the clinical outcome in routine clinical practice.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
110
Inclusion Criteria
  • patients who were 16 years of age or older
  • receiving voriconazole in order to treat invasive fungal infections or for empirical use
Exclusion Criteria
  • who experienced the serious side effect of voriconazole
  • were hypersensitive to azoles
  • had an aminotransferase, bilirubin, or alkaline phosphatase level higher than five times the upper limit of normal

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TDM of voriconazoleVoriconazole (therapeutic drug monitoring)-
Primary Outcome Measures
NameTimeMethod
side effectsduring 3 months
Secondary Outcome Measures
NameTimeMethod
treatment response to voriconazoleat 3 months
drug discontinuation of adverse eventswithin 3 month

Trial Locations

Locations (1)

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath